Latest Prostate cancer screening Stories
A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research Center confirms that a drug shown to reduce risk of prostate cancer by more than a third has no impact on lifespan but further reduces the risk of prostate cancer.
Both web-based and print-based decision aids appear to improve patients' informed decision making about prostate cancer screening up to 13 months later, but does not appear to affect actual screening rates.
Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test.
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo.
Men plan to continue getting prostate-specific antigen (PSA) tests despite recommendations that suggests men should not be screened, according to a new study by researchers at RTI International.
A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.